臨床外科78巻12号

2023年11月発行

特集 胃癌に対するconversion surgery—Stage Ⅳでも治したい！

総論

化学療法を開始した症例の何%がconversion surgeryの対象となるのか

著者： 河口賀彦¹ 丸山傑¹ 庄田勝俊¹ 赤池英憲¹ 市川大輔¹

所属機関： ¹山梨大学医学部第一外科

ページ範囲：P.1325 - P.1331

文献概要

【ポイント】
◆胃癌stage Ⅳのなかで大動脈周囲リンパ節に少量の転移であれば，化学療法後に約8割のR0手術が施行されている．
◆CY1P0症例において化学療法を施行後，R0手術の割合は4〜7割である．
◆多発肝転移を有する症例におけるconversion surgeryは約2割に施行されている．
◆腹膜播種を認める症例において化学療法施行後のR0手術の割合は約2割だが，腹腔内化学療法によりその治療成績は向上している．

参考文献

1）Bang YJ, Van Cutsem E, Feyereislova A, et al；ToGA Trial Investigators：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomized controlled trial. Lancet 376：687-697, 2010

2）Kang YK, Chen LT, Ryu MH, et al：Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients withHER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer（ATTRACTION-4）：a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23：234-247, 2022

3）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 3：215-221, 2008

4）Yamada Y, Higuchi K, Nishikawa K, et al：Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26：141-148, 2015

5）Yamada Y, Boku N, Mizusawa J, et al：Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer（JCOG1013）：an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 4：501-510, 2019

6）Yamaguchi K, Yoshida K, Tanahashi T, et al：The long-term survival of stage Ⅳ gastric cancer patients with conversion therapy. Gastric Cancer 21：315-323, 2018

7）Yoshida K, Yamaguchi K, Okumura N, et al：Is conversion therapy possible in stage Ⅳ gastric cancer：the proposal of new biological categories of classification. Gastric Cancer 19：329-338, 2016

8）Yoshikawa T, Sasako M, Yamamoto S, et al：Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96：1015-1022, 2009

9）Tsuburaya A, Mizusawa J, Tanaka Y, et al；Stomach Cancer Study Group of the Japan Clinical Oncology Group：Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101：653-660, 2014

10）Ito S, Sano T, Mizusawa J, et al：A phase Ⅱ study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis：JCOG1002. Gastric Cancer 20：322-331, 2017

11）Fujitani K, Yang HK, Mizusawa J, et al；REGATTA study investigators：Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor（REGATTA）：a phase 3, randomised controlled trial. Lancet Oncol 17：309-318, 2016

12）Aizawa M, Nashimoto A, Yabusaki H, et al：The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy. Surg Today 45：611-617, 2015

13）Yamaguchi T, Takashima A, Nagashima K, et al：Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology（CY1）or localized peritoneal metastasis（P1a）：a multi-institutional retrospective study. Gastric Cancer 24：701-709, 2021

14）Valletti M, Eshmuminov D, Gnecco N, et al：Gastric cancer with positive peritoneal cytology：survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World J Surg Oncol 19：245, 2021

15）Yoshida K, Yasufuku I, Terashima M, et al；CONVO-GC-1 Study Group：Federation of Asian Clinical Oncology（FACO）：International retrospective cohort study of conversion therapy for stage IV gastric cancer 1（CONVO-GC-1）. Ann Gastroenterol Surg 6：227-240, 2021

16）中村公紀，中森幹人，尾島敏康，他：【進行消化器癌のconversion surgery】胃癌 腹膜播種．外科80：23-27，2018

17）Yasufuku I, Nunobe S, Ida S, et al：Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer 23：319-327, 2020

18）Ding P, Yang P, Tian Y, et al：Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology：a prospective study. J Gastrointest Oncol 12：1416-1427, 2021

19）Yago A, Haruta S, Ueno M, et al：Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer：outcomes according to treatment strategy. World J Surg Oncol 20：35, 2022

20）Sato Y, Ohnuma H, Nobuoka T, et al：Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1（DCS）chemotherapy：a multi-institutional retrospective study. Gastric Cancer 20：517-526, 2017

21）Shirasu H, Tsushima T, Kawahira M, et al：Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer 21：338-344, 2018

22）Itani Y, Niinobu T, Nakagawa S, et al：A case of gastric cancer with liver metastasis resected after the combination chemotherapy with CDDP and TS-1. Gan To Kagaku Ryoho 32：1758-1760, 2005

23）Kagawa I, Nishiwaki K, Matsumoto Y, et al：A resected case of advanced gastric cancer with multiple liver metastasis responding to preoperative TS-1/CDDP chemotherapy. Gan To Kagaku Ryoho 33：1465-1468, 2006

24）Mitan M, Miyamoto M, Tsuda H, et al：A case of advanced gastric cancer with multiple liver metastases treated with preoperative TS-1/CDDP chemotherapy and resection, with a complete response and survival for 7 years. Gan To Kagaku Ryoho 41：1009-1012, 2014

25）Tsunematsu M, Takahashi N, Murakami K, et al：Successful conversion surgery for gastric cancer with multiple liver metastases treated after S-1 plus cisplatin combination chemotherapy：a case report. Surg Case Rep 3：95, 2017

26）Li ZY, Shan F, Zhang LH, et al：Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases. Genet Mol Res 13：10952-10957, 2014

27）Choda Y, Ninomiya M, Kanazawa T, et al：Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report. Gan To Kagaku Ryoho 41：1421-1424, 2014

28）高橋正純，川口大輔，山口直孝，他：同時性肝転移を有する胃癌に対する胃切除，肝切除，動注化学療法とS-1，trastuzumabの意義．癌の臨59：501-506，2013

29）Okabe H, Ueda S, Obama K, et al：Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 16：3227-3236, 2009

30）Kim SW：The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer 14：266-270, 2014

31）Ohnuma H, Sato Y, Hirakawa M, et al：Docetaxel, cisplatin and S-1（DCS）combination chemotherapy for gastric cancer patients with peritoneal metastasis：a retrospective study. Cancer Chemother Pharmacol 81：539-548, 2018

32）Zhang X, Huang H, Yang D, et al：Neoadjuvant intraperitoneal and systemic chemotherapy versus neoadjuvant systemic chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with peritoneal metastasis：a propensity score matched analysis. Technol Cancer Res Treat 20：15330338211036310, 2021

33）Kano Y, Ichikawa H, Hanyu T, et al：Conversion surgery for stage Ⅳ gastric cancer：a multicenter retrospective study. BMC Surg 22：428, 2022

34）Chan DY, Syn NL, Yap R, et al：Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready? J Gastrointest Surg 21：425-433, 2017

35）北山丈二，石神浩徳，山口博樹，他：【ガイドラインには書いていない-胃癌治療のCQ】Conversion surgeryの今　腹膜播種が消えたら胃切除術をするのか？　臨外75：1185-1189，2020

36）Yu P, Ye Z, Dai G, et al：Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis：a prospective cohort study. BMC Cancer 20：1108, 2020

37）Shi M, Yang Z, Lu S, et al：Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer 21：1344, 2021

38）Li Y, Lin H, Huang K, et al：Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer. J BUON 26：211-217, 2021

39）Yang ZY, Yuan F, Lu S, et al：Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis：a prospective phase II study. Front Oncol 12：905922, 2022

40）Shinkai M, Imano M：The clinical effect of conversion surgery for advanced gastric cancer patients with peritoneal metastasis. J Gastrointest Oncol 13：2169-2177, 2022

41）久森重夫，小濱和貴：切除不能進行胃癌に対するconversion surgeryの位置づけ．消外44：1859-1863，2021